Table 1.
Applications of mRNA-Encoded Antibodies
| Medical Area | Antibody Format | Indication | Developmental State | Company/Research Group |
|---|---|---|---|---|
| Oncology | bispecific | solid tumor | research | BioNTech AG90 |
| undisclosed | solid tumors | pre-clinical | BioNTech AG | |
| IgG | CD20 | research | CureVac AG89 | |
| undisclosed | superficial tumors | pre-clinical | CureVac AG | |
| Infectious diseases | IgG | HIV | research | University of Pennsylvania92 |
| IgG | rabies | research | CureVac AG89 | |
| IgG | influenza B | research | CureVac AG89 | |
| IgG | influenza A | research | Moderna Therapeutics42 | |
| various | RSV | research | Georgia Institute of Technology and Emory University106 | |
| undisclosed (mRNA-1944) | Chikungunya virus | phase 1 | Moderna Therapeutics/DARPA | |
| Toxins | VNA | Botulinum toxin | research | CureVac AG89 |
| VNA | Shiga toxin | research | CureVac AG89 | |
| Undisclosed | undisclosed | molecular therapies | pre-clinical | CureVac AG |
DARPA, Defense Advanced Research Projects Agency.